CTLA4 and lung cancer: Immune oncology treatments, such as immune-checkpoint inhibitors that target programmed cell death (PD)-1, PD-ligand (PD-L) 1, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are routinely used in lung cancer.